Quantcast

Latest C-peptide Stories

2010-05-11 08:03:00

CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S.

2010-05-06 08:10:00

JERUSALEM, Israel, May 6, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc.

2010-05-04 06:30:00

CRANBURY, N.J., May 4 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today.

2010-02-25 09:01:00

ST. LOUIS, Feb. 25 /PRNewswire/ -- Supelco, a division of Sigma-Aldrich® (Nasdaq: SIAL), announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core(TM) particle design.

2010-01-26 14:00:00

SALEM, N.H., Jan. 26 /PRNewswire/ -- ALPCO Diagnostics has developed two new low-sample volume ELISAs for the quantitative analysis of total proinsulin (I and II) in rats and mice.

2010-01-07 06:55:00

CAMBRIDGE, Mass., Jan. 7 /PRNewswire/ -- Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

2009-12-01 06:30:00

CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No.

2009-10-07 17:29:00

BOULDER, Colo., Oct. 7 /PRNewswire/ -- Waleed Danho, Ph.D., Distinguished Research Leader at Roche was honored last week as the 2009 recipient of the Meienhofer Award for excellence in peptide chemistry at the international peptide symposium, RCCPS (http://www.rochecolorado.com/PeptideSymp09/).

2009-09-29 06:00:00

SAN FRANCISCO, Sept. 29 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced the appointment of Arie S. Belldegrun, M.D., FACS to its board of directors. Dr.

2009-09-25 06:00:00

SAN FRANCISCO, Sept. 25 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced the appointment of Frank Litvack, M.D., to its Board of Directors. Dr.


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.